Europe approves Nexavar for HCC

The European Commission approved Nexavar sorafenib from Bayer (FSE:BAY; BAY) and Onyx (ONXX) to treat hepatocellular carcinoma (HCC). The inhibitor of multiple kinases already is approved to treat adv...